Insider planned share sales for CLOV (CLOV) disclosed in filing Form 144
Rhea-AI Filing Summary
An insider of CLOV has filed a Form 144 indicating an intent to sell 2,102 shares of common stock through broker Morgan Stanley Smith Barney LLC on or about January 7, 2026 on the NASDAQ. These shares were acquired on January 3, 2026 as restricted stock units from the issuer. The filing notes that 424,304,898 common shares were outstanding. Over the prior three months, the same seller completed additional common stock sales labeled as “10b5-1 Sales”.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What is the recent selling history for this CLOV insider under 10b5-1?
The filing lists 10b5-1 Sales for JAMIE REYNOSO of 4,913 shares on December 18, 2025, 30,385 shares on November 4, 2025, and 16,514 shares on October 17, 2025, all in common stock.
What gross proceeds were reported from recent CLOV stock sales?
The Form 144 reports gross proceeds of $12,813.60 on December 18, 2025, $108,854.26 on November 4, 2025, and $44,376.42 on October 17, 2025 from common stock sales.
On which exchange and around what date is the new CLOV sale expected?
The planned sale of 2,102 CLOV common shares is noted with an approximate sale date of January 7, 2026 and names the NASDAQ as the securities exchange.
What representation does the CLOV insider make by signing the Form 144?
By signing, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.